Abstract Library

#4656 Development of a 3D patient-derived extracellular matrix hydrogel model of small intestinal neuroendocrine tumour and mesenteric fibrosis

Introduction: The pathogenesis of mesenteric fibrosis in small intestinal neuroendocrine tumours (SI-NETs) is poorly understood, limiting development of effective treatments and biomarkers. A major barrier to research is the lack of disease models.

Conference:

Presenting Author:

Authors: Hodgetts H, Martins M, Luong T, Hall A, Webster A,

Keywords: small intestine, neuroendocrine, 3D model, hydrogel, fibrosis,

#4449 Treatment of MiNEN with peptide receptor radionuclide therapy

Introduction: Mixed non-neuroendocrine and neuroendocrine neoplasms (MiNENs) of gastrointestinal tract are rare tumours with characteristic histological features include at least 30% of both neuroendocrine and non-neuroendocrine components of the whole neoplasm. They are usually treated with surgical resection and chemotherapy in advanced disease. However, there is scarcity of data for the use of peptide receptor radionuclide therapy (PRRT) in these tumours.

Conference:

Presenting Author: Shekhda K

Authors: Shekhda K, Luong T, Paterson A, Navalkissoor S, Krell D,

Keywords: MiNEN, PRRT, DOTATATE,

#4322 Clinical outcomes of patients with rectal neuroendocrine tumours smaller than 10mm after endoscopic resection

Introduction: Rectal neuroendocrine tumours (r-NETs) generally have a good prognosis, but up to 20% may be misdiagnosed during endoscopy, risking inadequate treatment. Prognosis factors include tumour size, grading, staging, and lymphovascular invasion, with guidelines recommending endoscopic resection for small, low-grade lesions.

Conference:

Presenting Author:

Authors: Dell' Unto E, Riding G, Rimondi A, Panzuto F, Luong T,

Keywords: Rectal Carcinoid, Rectal Neuroendocrine Tumour, Endoscopic Resection,

#4041 Mesenteric fibrosis in small intestinal neuroendocrine tumors (SI-NETs): Pathogenesis and therapeutic targets

Introduction: Mesenteric fibrosis (MF) affects up to 50% of small intestine neuroendocrine tumor (SI-NET) patients, causing significant morbidity and mortality. MF pathophysiology is poorly understood, limiting treatment development and biomarker identification.

Conference:

Presenting Author:

Authors: Castanho Martins M, Hodgetts H, Lemos Dias M, Luong T, Hall A,

Keywords: fibrosis, small intestine, 3D model, cell crosstalk, microenvironment, cancer-associated fibroblast,

#3651 Mesenteric fibrosis in small intestinal neuroendocrine tumors (SI-NETs) – Steps towards understanding its pathogenesis

Introduction: Mesenteric fibrosis (MF) occurs in 50% of patients with SI-NETs, causing significant morbidity and mortality. The pathogenesis of MF in SI-NETs is incompletely understood with no biomarkers or radiological criteria to predict long-term complications of SI-NET associated MF.

Conference:

Presenting Author:

Authors: Hodgetts H, Martins M, Luong T, Hall A, Thirlwell C,

Keywords: small, intestine, neuroendocrine tumor, fibrosis, mesenteric, rna-sequencing, biomarker,